Summary
The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
Conditions
Duchenne Muscular Dystrophy
Recruitment Status
Terminated
Eligibility Criteria
Inclusion Criteria:
Completed a clinical trial evaluating casimersen or golodirsen, per protocol.
Is between 7 and 23 years of age, inclusive, at enrollment.
Other inclusion/exclusion criteria apply.
Intervention
Intervention Type
Intervention Name
Drug
Casimersen
Drug
Golodirsen
Phase
Phase 3
Gender
Male
Min Age
7 Years
Max Age
23 Years
Download Date
August 21, 2023
Principal Investigator
N/A
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
Contact
For more information and to contact the study team:
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
NCT03532542